{"disease":{"id":"unfavourable-intermediate-risk-prostate-cancer","name":"unfavourable intermediate risk prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}